Shares of AstraZeneca closed up 12.16% on Monday with about 26.5 million shares traded. The stock was one of the biggest gainers on the NYSE and hit a new 52-week high of $79.90 during intra-day trading. Pfizer is looking to acquire AstraZeneca. Pfizer bid on the company previously in January for $76.62 a share in cash and stock. AstraZeneca turned that down, but Pfizer contacted it again on April 26, trying to begin discussions again.
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) - For an in-depth report on Furiex Pharmaceuticals, Inc follow: www.BullTrends.com/stockquote/FURX
Shares of Furiex Pharmaceuticals closed up 28.57% on about 4.7 million shares traded on Tuesday. The stock was one of the biggest gainers on the NASDAQ. The big jump came after it was revealed that Forest Laboratories would acquire Furiex for $1.5 billion. Actavis recently announced that it would buy Forest for approximately $25 billion in a deal that should close in mid-2014. Forest said Monday that Actavis agreed to and supports the Furiex acquisition, according to USA Today.
Splunk, Inc. (NASDAQ: SPLK) – For an in-depth report on Splunk, Inc. follow: www.BullTrends.com/stockquote/SPLK
Shares of Splunk Inc. closed down nearly 5% on Monday with nearly 6 million shares traded. The stock was one of the most active stocks on the NASDAQ. Earlier this month the company announced that it has been named as one of the “Best Places to Work” in the Bay Area by San Francisco Business Times and Silicon Valley Business Journal. This is the seventh consecutive year Splunk has been named a top Bay Area employer.
ZAP (OTC: ZAAP) – For an in-depth report on ZAP follow: www.BullTrends.com/stockquote/ZAP
Shares of ZAP closed up nearly 5% on Monday with about 5.3 million shares traded. The stock was one of the most active stocks in the OTC market. The company, jointly with Jonway Auto, its subsidiary in Zhejiang, China, announced the receipt of 25,000 committed direct orders for its newest EV models of URBEE and SPARKEE.
Disclosure: BullTrends.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.